Management of failure of infliximab in inflammatory bowel disease

##plugins.themes.academic_pro.article.sidebar##

Published Jun 9, 2011
Download
pdf
Vol. 89 No. 6 (2011): Issue Jun 2011

##plugins.themes.academic_pro.article.main##

Narjess Naija
Sami Karoui
Meriem Serghini
Lamia Kallel
Jalel Boubaker
Azza Filali

Abstract

Background: Infliximab is a chimeric monoclonal anti TNFa whose effectiveness during IBD has been demonstrated especially in Crohn's disease and more recently in the course of ulcerative colitis. However, a significant number of patients estimated to be between 20 to 30% of patients with crohn’s disease and 30 to 40% with ulcerative colitis, not responding to treatment with infliximab, thus the failure of infliximab is a real problem which the clinician should resolve quickly.
This review aimed to describe predictif factors and mecanique of infliximab failure during MICI treatment and to precise differents therapeutique options.
Methods: Literature review
Results: The definition of failure of infliximab during inflammatory bowel disease is not consensual; it is very varied from one study to another. However, we define two types of non response to infliximab as either primary or secondary. Factors predisposing to failure of infliximab have been reported. Some alternative therapies may be recommended.
The sequential treatment comparing to the episodic treatment by infliximab is better in obtaining an endoscopic and clinical response of patients with inflammatory bowel disease. The injection of infliximab should be preceded by the taking of immunosuppressive and concomitant use of these during treatment significantly improves the clinical response of patients. Also, the increased time of exposure to infliximab, either by increasing doses or shorter intervals of infusion therapy is a considerable therapy alternative. Moreover, thanks to the advent of new molecular anti TNFa, a relay by adalinumab or certolizumab may be proposed.
Conclusion: The failure of infliximab is a common situation but not so easily solved by the clinician. The alternative therapies are aimed at strengthening; improve the action of infliximab or to change the therapeutic molecule. The efficacy of infliximab, being dependent on the rate of infliximab antibody, a therapeutic strategy based on the serum concentration of infliximab is proposed. If the serum concentration is low or undetectable suggesting a high rate of antibody, a change of molecule should be promoted. As if against the serum concentration is high or intermediate, increased time of exposure to infliximab or the addition of immunosuppressive can be proposed.

Keywords:

Infliximab, Crohn's disease, ulcerative colitis

##plugins.themes.academic_pro.article.details##

References

  1. Van Assche G, Vermeire S, Rutgeerts P. Management of loss of response to anti-TNF drugs: Change the dose or change the drug? J Crohn colitis 2008;2:348-51.
  2. Karoui S, Boubaker J, Filali A. Indications et résultats de l'infliximab au cours de la maladie de Crohn. Tunis Med 2004; 82:1057-1063.
  3. Pender SL, Fell JM, Chamow SM, Ashkenazi A, MacDonald TT. A p55 TNF receptor immunoadhesion prevents T cell-mediated intestinal injury by inhibiting matrix metalloproteinase production. J Immunol 1998;160:4098-4103.
  4. Sands B, Van Deventer S, Bernstein C et al. Long term treatment of fistulizing Crohn's disease: response to infliximab in ACCENT II trial through 54 weeks. Gastroenterology 2002;122:A81.
  5. Shao LM, Chen MY, Chen QY, Cai JT. Meta-analysis : the efficacy and safety of certolizumab pegol in Crohn's disease. Aliment Pharmacol Ther 2009;29:605-14.
  6. Sandborn WJ, Rutgeerts P, Enns R et al. Adalinumab induction therapy for Crohn disease previously treated with infliximab. Ann Intern Med 2007; 146: 829-38.
  7. Rutgeerts P, Van Assche G, Vermeire S. Infliximab therapy for inflammatory bowel disease-seven years on. Aliment Pharmacol Ther 2006;23:451-63.
  8. Hanauer SB, Feagan BG, Lichtensein GR et al. Maintenance infliximab for Crohn's disease: The ACCENT I randomised trial. Lancet 2002;359:1541-49.
  9. Rutgeerts P, Feagan BG, Lichtensein GR et al. Comparison of Scheduled and Episodic Treatment Strategies of Infliximab in Crohn's disease. Gastroenterology 2004;126:402-413.
  10. Rutgeerts P, Diamond RH, Bala M et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointestinal Endoscopy 2006;63:433-42.
  11. Vermeire S, Noman M, Gert Van Assche et al. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut 2007;56:1226-31.
  12. Baert F, Noman M, Vermeire S et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003;348:601-8.
  13. Schnitzer F, Fidder H, Ferrante M et al. Long -term outcome of treatment with infliximab in 440 Crohn's disease patients: results from a single center cohort. Gastroenterology 2007;132:A-14520.
  14. Hanauer SB, Sandborn WJ, Rutgeerts P et al. Human Anti-Tumor Necrosis Factor Monoclonal Antibody (Adalimumab) in Crohn's disease: The CLASSIC-I Trial. Gastroenterology 2006; 130: 323-33.
  15. Colombel JF, Sandborn WJ, Rutgeerts P et al. Adalimumab for maintenance of clinical response and remission in pateints with Crohn's disease: The CHARM Trial. Gastroenterology 2007; 132: 52-65.
  16. Oussalah A, Babouri A, Chevaux JB et al. Adalinumab for Crohn's disease with intolerance or lost response to infliximab: a 3-year single-centre experience. Aliment Pharmacol Ther 2009;29: 416-23.
  17. Sandborn WJ, Feagan BG, Stoinov S et al. Certolizumab Pegol for the treatment of Crohn's disease. N Engl J Med 2007; 357: 228-38.
  18. Schreiber S, Kareemi MK, Lawrance I et al. Maintenance Therapy with Certolizumab Pegol for Crohn's disease. N Engl J Med 2007;357:239-50.
  19. Vermeire S, Abreu MT, D'Haens G et al. Efficacy and safety of certolizumab pegol in patients with active Crohn's disease who previously lost response or were intolerant to infliximab: openlabel induction preliminary results of the WELCOM study. Gastroenterology 2008;134:A67.
  20. Danese S, Mocciaro F, Guidi L et al. Successful induction of clinical response and remission with certolizumab pegol in Crohn's disease patients refractory or intolerant to infliximab: a real-life multicenter experinece of compassionate use. Inflamm Bowel Dis 2008;14: 1168-70.
  21. Maser EA, Deconda D, Lichtiger S et al. Cyclosporine and infliximab as Rescue Therapy for Each Other in Patients with Steroïd-Refractory Ulcerative colitis. Clin Gastroenterol Hepatol 2008;6:1112-116.